Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia

Amy Crowe, Nicole McMahon, Bart Currie, Robert Baird

    Research output: Contribution to journalArticleResearchpeer-review

    2 Downloads (Pure)

    Abstract

    Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.
    Original languageEnglish
    Pages (from-to)160-162
    Number of pages3
    JournalInternational Journal of Antimicrobial Agents
    Volume44
    Issue number2
    DOIs
    Publication statusPublished - Aug 2014

    Fingerprint

    Northern Territory
    Melioidosis
    Burkholderia pseudomallei
    meropenem
    Sulfamethoxazole Drug Combination Trimethoprim
    Ceftazidime
    Disk Diffusion Antimicrobial Tests
    Northern Asia
    Southeastern Asia
    Doxycycline
    Thailand
    Gram-Negative Bacteria
    Communicable Diseases
    Guidelines

    Cite this

    @article{2ca6a63123e24b109d08e8c8a0153852,
    title = "Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia",
    abstract = "Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6{\%}) were susceptible to doxycycline and 232 (99.1{\%}) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.",
    keywords = "ceftazidime, cotrimoxazole, doxycycline, meropenem, antiinfective agent, thienamycin derivative, antibiotic resistance, antibiotic sensitivity, article, Australia, bacterium isolate, Burkholderia pseudomallei, controlled study, disease duration, geographic origin, melioidosis, minimum inhibitory concentration, nonhuman, onset age, priority journal, drug effects, human, isolation and purification, microbial sensitivity test, microbiology, root cause analysis, Anti-Bacterial Agents, Ceftazidime, Drug Resistance, Bacterial, Humans, Melioidosis, Microbial Sensitivity Tests, Northern Territory, Root Cause Analysis, Thienamycins, Trimethoprim-Sulfamethoxazole Combination",
    author = "Amy Crowe and Nicole McMahon and Bart Currie and Robert Baird",
    year = "2014",
    month = "8",
    doi = "10.1016/j.ijantimicag.2014.04.012",
    language = "English",
    volume = "44",
    pages = "160--162",
    journal = "International Journal of Antimicrobial Agents",
    issn = "0924-8579",
    publisher = "Elsevier",
    number = "2",

    }

    Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. / Crowe, Amy; McMahon, Nicole; Currie, Bart; Baird, Robert.

    In: International Journal of Antimicrobial Agents, Vol. 44, No. 2, 08.2014, p. 160-162.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia

    AU - Crowe, Amy

    AU - McMahon, Nicole

    AU - Currie, Bart

    AU - Baird, Robert

    PY - 2014/8

    Y1 - 2014/8

    N2 - Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.

    AB - Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.

    KW - ceftazidime

    KW - cotrimoxazole

    KW - doxycycline

    KW - meropenem

    KW - antiinfective agent

    KW - thienamycin derivative

    KW - antibiotic resistance

    KW - antibiotic sensitivity

    KW - article

    KW - Australia

    KW - bacterium isolate

    KW - Burkholderia pseudomallei

    KW - controlled study

    KW - disease duration

    KW - geographic origin

    KW - melioidosis

    KW - minimum inhibitory concentration

    KW - nonhuman

    KW - onset age

    KW - priority journal

    KW - drug effects

    KW - human

    KW - isolation and purification

    KW - microbial sensitivity test

    KW - microbiology

    KW - root cause analysis

    KW - Anti-Bacterial Agents

    KW - Ceftazidime

    KW - Drug Resistance, Bacterial

    KW - Humans

    KW - Melioidosis

    KW - Microbial Sensitivity Tests

    KW - Northern Territory

    KW - Root Cause Analysis

    KW - Thienamycins

    KW - Trimethoprim-Sulfamethoxazole Combination

    U2 - 10.1016/j.ijantimicag.2014.04.012

    DO - 10.1016/j.ijantimicag.2014.04.012

    M3 - Article

    VL - 44

    SP - 160

    EP - 162

    JO - International Journal of Antimicrobial Agents

    JF - International Journal of Antimicrobial Agents

    SN - 0924-8579

    IS - 2

    ER -